Last reviewed · How we verify
anti-CD19 anti-CD20 Bispecific CAR-T
anti-CD19 anti-CD20 Bispecific CAR-T is a Biologic drug developed by Beijing Doing Biomedical Co., Ltd.. It is currently in Phase 1 development.
At a glance
| Generic name | anti-CD19 anti-CD20 Bispecific CAR-T |
|---|---|
| Sponsor | Beijing Doing Biomedical Co., Ltd. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy (PHASE2)
- CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies (PHASE1, PHASE2)
- Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (PHASE2)
- Fully Human Bispecific Anti-CD20, Anti-CD19 CAR T Cells for Patients With Relapsed and/or Refractory B Cell Malignancies (PHASE1)
- A Study of C-CAR039 (Prizloncabtagene Autoleucel) in Patients With Relapsed/Refractory Large B-Cell Lymphoma (PHASE1, PHASE2)
- Bispecific CAR T Cells for B-cell Malignancies (BaseCAR-01 Trial) (PHASE1)
- Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia (PHASE1)
- Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T Therapy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- anti-CD19 anti-CD20 Bispecific CAR-T CI brief — competitive landscape report
- anti-CD19 anti-CD20 Bispecific CAR-T updates RSS · CI watch RSS
- Beijing Doing Biomedical Co., Ltd. portfolio CI
Frequently asked questions about anti-CD19 anti-CD20 Bispecific CAR-T
What is anti-CD19 anti-CD20 Bispecific CAR-T?
anti-CD19 anti-CD20 Bispecific CAR-T is a Biologic drug developed by Beijing Doing Biomedical Co., Ltd..
Who makes anti-CD19 anti-CD20 Bispecific CAR-T?
anti-CD19 anti-CD20 Bispecific CAR-T is developed by Beijing Doing Biomedical Co., Ltd. (see full Beijing Doing Biomedical Co., Ltd. pipeline at /company/beijing-doing-biomedical-co-ltd).
What development phase is anti-CD19 anti-CD20 Bispecific CAR-T in?
anti-CD19 anti-CD20 Bispecific CAR-T is in Phase 1.